Search Results - nanobodies

5 Results Sort By:
Single Domain Antibodies Targeting the S2 Subunit of SARS-CoV-2 Spike Protein
Abstract: The COVID-19 pandemic is a worldwide public health crisis with over 100 million confirmed cases and 2.4 million deaths as of February 2021. COVID-19 is caused by a novel coronavirus called SARS-CoV-2. Almost all the neutralizing antibodies targeting SARS-CoV-2 that are in development recognize the receptor binding domain (RBD) on the spike...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Zhijian Duan, Jesse Buffington
Keywords(s): : COVID-19, ANTIBODY, Camel Nanobody, CORONAVIRUS, HO, Infectious Diseases, Nanobodies, Pandemic, SARS-CoV-2, Shark Nanobody, therapeutic, Vaccine
Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease
High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors
Abstract: CD276 (also called B7-H3) is a pan-cancer antigen expressed in multiple solid tumors and an emerging cancer target. CD276 protein is overexpressed in pancreatic cancer, prostate cancer, breast cancer, colon cancer, lung cancer, and brain tumors (such as neuroblastoma) – making it an ideal target for cancer therapy.  Investigators at the National...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Brad St. Croix, Ruixue Wang, Dan Li
Keywords(s): ADC, Antibody-drug Conjugate, B7-H3, BREAST CANCER, CAR, CD276, chimeric antigen receptor, COLON CANCER, Glioma, HO, lung cancer, Nanobodies, Neuroblastoma, OVARIAN CANCER, Pancreatic Cancer, solid tumors
Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology
Nanobodies Neutralizing Lassa Virus
Abstract: Lassa Hemorrhagic Fever (LHF) is a serious disease caused by infection with Lassa virus (LASV) – highly prevalent in West Africa and spreading globally. LASV is associated with high morbidity and mortality rates, annually infecting 100,000 to 300,000 individuals and causing 5,000 deaths. Developing prophylactics and treatment for LASV is difficult...
Published: 9/26/2024   |   Inventor(s): Mitchell Ho, Peter Kwong, Zhijian Duan, Yaping Sun, Sao Cheung, Jason Gorman
Keywords(s): antibodies, diagnostic, HO, LASSA, Lassa Hemorrhagic Fever, LHF, Nanobodies, Neutralizing, virus
Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease
Camel VHH Nanobodies Bind the S2 Subunit of SARS-CoV-2 and Broadly Neutralize Variants including Omicron
Abstract: Since its emergence in 2019, COVID-19 infected over 600 million people and over 6 million people have died from the disease. COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Neutralizing antibodies have been developed to bind to the receptor binding domain (RBD) on the spike (S) protein. Blocking the interaction of the RBD...
Published: 7/29/2024   |   Inventor(s): Mitchell Ho, Jessica Hong, Jesse Buffington, Zhijian Duan
Keywords(s): ANTIBODY, Camel Nanobody, CORONAVIRUS, COVID-19, HO, Infectious Diseases, Nanobodies, Pandemic, SARS-CoV-2, therapeutic, Vaccine
Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease, Application > Therapeutics, Collaboration Sought > Licensing
Single-Chain Antibodies Directed to Norovirus GI.1 and GII.4 and Their Use
Vaccines and therapies to prevent and treat Norovirus infections are not available, despite the worldwide prevalence of Norovirus infections. Outbreaks of human gastroenteritis attributable to Norovirus commonly occur in group settings, such as hospitals, nursing homes, schools, dormitories, cruise ships and military barracks. This application claims...
Published: 10/28/2024   |   Inventor(s): Karin Bok, Stanislav Sosnovtsev, Lisbeth Kim Green, Gladys Parreno, Andrea Aguilar, Marina Bok, Lorena Garaicoechea
Keywords(s): DA4BXX, DA4XXX, DAXXXX, DB4BXX, DBXXXX, DD1XXX, DDXXXX, DEXXXX, diagnostic, Listed LPM Fenn as of 4/15/2015, Nanobodies, Norovirus, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Specific, therapeutic
Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Infectious Disease, Application > Research Materials, Application > Diagnostics